Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,596 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 21,132 · Balance 52,728 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 12,429 · Balance 65,157 Row 3 · 2026-08-25 · Sale · Disposed 33,561 · Balance 31,596 F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 7,044 |
Reported balance
After 2026-08-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-25 · Exercise / conversion · Disposed 21,132 · Balance 7,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 12,429 |
Reported balance
After 2026-08-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-25 · Exercise / conversion · Disposed 12,429 · Balance 12,429 |
| Common StockSEC Table I · non-derivative | Indirect2024 GRAT | 5,423 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,423 |
| Common StockSEC Table I · non-derivative | Indirect2025 GRAT | 10,780 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,780 |
| Common StockSEC Table I · non-derivative | Indirect2026 GRAT | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,611 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 155,611 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust Held By Spouse | 10,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $87.76 | $43,880.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,577 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.76 | $17,551.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,077 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $87.75 | $26,325.00 |
DisclosureSEC source: 0001127602-17-008154 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,277 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $88.43 | $17,686.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 24 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,515 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 88 | $88.41 | $7,779.64 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 23 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,715 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $88.40 | $8,839.50 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,803 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 12 | $88.39 | $1,060.68 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,903 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $88.37 | $17,674.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,915 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $88.34 | $8,834.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,115 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $88.32 | $8,832.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,215 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $88.31 | $17,662.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,315 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $88.29 | $35,316.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,515 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $88.29 | $17,657.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,915 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $88.25 | $44,125.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,115 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $88.25 | $8,824.50 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,615 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $88.22 | $8,822.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,715 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 102 | $88.21 | $8,997.42 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,815 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $88.06 | $8,806.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,917 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $88.05 | $8,805.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,017 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $88.04 | $8,804.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,117 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1 | $88.03 | $88.03 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,217 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $88.02 | $8,802.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,218 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 201 | $88.01 | $17,690.01 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,318 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $88.00 | $8,800.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,519 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.99 | $8,799.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,619 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.99 | $8,798.50 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,719 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.98 | $8,798.00 |
DisclosureSEC source: 0001127602-17-008157 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,819 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 21,779 | $0.00 Strike: $40.40 | $0.00 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · derivative · entry 27 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,779 shares Expires 2020-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.75 | $8,774.50 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 26 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,577 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,200 | $87.73 | $105,276.00 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 25 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,677 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.73 | $17,545.00 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 24 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,877 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 192 | $87.72 | $16,842.24 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 23 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,077 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 293 | $87.71 | $25,699.03 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,269 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.70 | $17,540.00 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,562 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 7 | $87.70 | $613.87 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,762 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,120 | $87.69 | $98,212.80 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,769 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $87.68 | $43,840.00 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,889 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.68 | $8,767.50 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,389 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,000 | $87.67 | $87,670.00 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,489 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 190 | $87.67 | $16,656.35 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,489 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 601 | $87.66 | $52,683.66 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,679 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 199 | $87.66 | $17,443.35 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,280 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $87.65 | $43,825.00 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,479 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 610 | $87.64 | $53,460.40 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,979 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.64 | $8,763.50 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,589 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $87.63 | $26,289.00 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,689 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $87.63 | $17,525.00 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,989 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $87.62 | $8,762.00 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,189 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5 | $87.53 | $437.65 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,289 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $87.50 | $35,000.00 |
DisclosureSEC source: 0001127602-17-008150 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,294 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.